HHS, FDA Announce Multiple Initiatives on Food Safety, Quality and Compliance Fronts

March 24, 2025

Reading Time : 2 min

In the past week, the U.S. Food and Drug Administration (FDA), in collaboration with the Department of Health and Human Services (HHS) announced three new initiatives related to food safety and food supply chain transparency. Outlined below, these new initiatives align with HHS Secretary Robert F. Kennedy Jr.’s recent announcements to focus on bolstering food safety, including the recent directive to the FDA to explore the revision of the longstanding Generally Recognized as Safe (GRAS) rule.

Operation Stork Speed

On March 18, 2025, HHS and FDA announced “Operation Stork Speed,” aimed at enhancing the safety, nutritional quality and availability of infant formula. Through this initiative, FDA plans to increase testing for heavy metals and other contaminants in infant formula. The agency is also calling on industry to “develop new infant formulas and clarify opportunities to help inform consumers about formula ingredients.” The agency states that it will use “both longstanding and newly granted” authorities to carry out its stated goals, including:

  • Issuing a Request for Information (RFI) to start a comprehensive update and review of infant formula nutrients;
  • Increasing testing for heavy metals and other contaminants in infant formula and other children foods;
  • Extending the personal importation policy; and
  • Working with both industry and consumer stakeholders to increase transparency and collaborating with the National Institutes of Health (NIH) and other scientific bodies to address scientific research gaps related to health outcomes associated with formula feeding.

Chemical Contaminants Transparency Tool for Foods

On March 20, 2025, the agency unveiled the Chemical Contaminants Transparency Tool (CCT Tool), a searchable online database that consolidates information on contaminant levels in human foods. The database lists the contaminant name, commodity, contaminant level type, level value and reference. To date, FDA has published a variety of contaminant levels for poisonous or deleterious substances in food in various guidance documents and regulations for industry. With the CCT Tool, the agency aims to consolidate this information for ease of reference. Certain contaminant levels such as allowable levels listed in the quality standard for bottled water and marine biotoxin safety levels are not included in the tool.

Extension of Compliance Date for Food Traceability Rule

Also, on March 20, 2025, the agency announced its intention to extend the compliance date for its 2022 final rule on Requirements for Additional Traceability Records for Certain Foods (Food Traceability Final Rule) by 30 months. Implementing Section 204(d) of the Food Safety Modernization Act (FSMA), the Food Traceability Rule mandates enhanced recordkeeping requirements for certain high-risk foods to improve the agency’s ability to respond to foodborne illness outbreaks and contamination events. Citing concerns among covered entities about meeting the initial compliance deadline of January 2026, FDA plans to extend the compliance date using notice and comment rulemaking at a later date. FDA intends to engage with stakeholders and assist industry with implementation.

Industry participants should expect to see further policy updates and closely monitor forthcoming guidance.

 

Share This Insight

Previous Entries

Eye on FDA

March 13, 2026

In March 2026, the Food and Drug Administration (FDA) issued draft guidance for the industry, New Clinical Investigation Exclusivity (3-Year Exclusivity) for Drug Products: Questions and Answers, providing additional clarity on eligibility for and requests for 3-year exclusivity under the Federal Food, Drug and Cosmetic Act for qualifying drug products.

...

Read More

Eye on FDA

February 24, 2026

On February 23, 2026, the Food and Drug Administration (FDA) released a draft guidance entitled “Considerations for the Use of the Plausible Mechanism Framework to Develop Individualized Therapies that Target Specific Genetic Conditions with Known Biological Cause.” This guidance is designed for targeted, individualized therapies for which randomized controlled trials are not practical due to a small patient population, and was previewed by the Commissioner in several public forums.

...

Read More

Eye on FDA

February 17, 2026

On February 3, 2026, the Consolidated Appropriations Act, 2026 (P.L. 119-75) became law and marked an important milestone in the bipartisan congressional effort to reauthorize the rare pediatric disease priority review voucher program. Section 6604 of this law extends the Food and Drug Administration’s (FDA) authority to issue priority review vouchers to encourage treatments for rare pediatric diseases through September 30, 2029.

...

Read More

Eye on FDA

February 17, 2026

In case you missed it, Department of Health and Human Services Secretary Robert F. Kennedy Jr. and former Food and Drug Administration (FDA) Commissioner David Kessler appeared on 60 Minutes this past Saturday, February 15, in a segment titled “Generally Recognized as Safe.” As the title suggests, the conversation centered on FDA’s Generally Recognized as Safe (GRAS) regulatory pathway (for background, see our prior post discussing in more detail the GRAS process), as well as Commissioner Kessler’s August 2025 citizen petition urging FDA to revoke the GRAS status of refined carbohydrates used in industrial food processing (discussed in more detail in our earlier coverage of the petition).

...

Read More

© 2026 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.